Integrating disease and drug-related phenotypes for improved identification of pharmacogenomic variants.

To improve the identification and interpretation of pharmacogenetic variants through the integration of disease and drug-related traits. We hypothesized that integrating genome-wide disease and pharmacogenomic data may drive new insights into drug toxicity and response by identifying shared genetic architecture. Pleiotropic variants were identified using a methodological framework incorporating colocalization analysis.